aTYR PHARMA INC
ATYRaTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ATYR1940 | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in aTYR PHARMA INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in aTYR PHARMA INC's (ATYR) pipeline across Phase 2. Its lead program is ATYR1940 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is aTYR PHARMA INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for aTYR PHARMA INC (ATYR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATYR biotech catalysts?→
Add ATYR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow aTYR PHARMA INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.